Who is sponsoring COBRA-REDUCE?

COBRA-REDUCE is sponsored by CeloNova BioSciences, Inc..

What condition does COBRA-REDUCE study?

COBRA-REDUCE studies Angina, Stable, Angina, Unstable, Anticoagulants.

What drugs are being tested in COBRA-REDUCE?

Interventions: COBRA PzF, Drug Eluting Stent.

What is the status of COBRA-REDUCE?

COBRA-REDUCE is currently UNKNOWN.

Last reviewed 2020-10-23 · How we verify

COBRA PzF Stenting to Reduce the Duration of Triple Therapy in Patients Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention (COBRA-REDUCE)

NCT02594501 NA UNKNOWN

The purpose of this study is to determine whether patients undergoing coronary intervention that also require oral anticoagulation, treatment with the COBRA PzF stent plus 14-day dual anti-platelet therapy (DAPT) has higher safety and non-inferior outcomes for thrombo-embolic events than compared with standard FDA-approved drug eluting stent (DES) plus 3 or 6-month DAPT.

Details

Lead sponsor	CeloNova BioSciences, Inc.
Phase	NA
Status	UNKNOWN
Enrolment	996
Start date	2016-02-05
Completion	2021-11

Conditions

Angina, Stable
Angina, Unstable
Anticoagulants

Interventions

COBRA PzF
Drug Eluting Stent

Primary outcomes

BARC class >=2 bleeding after hospital discharge (or beyond 14 days, whichever is "later"). — 6 months
Composite of all cause death, myocardial infarction, definite and probable stent thrombosis or ischemic stroke — 6 months

Countries

United States, Belgium, Denmark, France, Germany, Italy, Latvia, Switzerland